HELIKIT
MAYOLY SPINDLER
Identification
- Active ingredient (INN)
- UREE 13C
- Internal code
- 10 S 160
- Country of Origin
- France
- Pharmaceutical form
- Powder for Oral Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- flacon de poudre
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
This medicine is for diagnostic use only.
In vivo diagnosis of
Helicobacter pylori infection, including control of eradication.
In adults.
Refer to the official national recommendations for the treatment of Helicobacter pylori infections.
Associated Conditions
- gastroctomy (accelerated gastric emptying);
- taking a known treatment to reduce bacterial load in Helicobacter pylori over the last 2 weeks for proton pump inhibitors and in the last 4 weeks for antibiotics.
In particular cases of type
A gastritis (pathology mainly affecting the elderly), respiratory testing may give false positive results; therefore, HELIKIT is contraindicated.
Other tests may be required to exclude the presence of Helicobacter pylori.
On the other hand, infections with germs producing lurease, other than Helicobacter pylori, may also give false positive results.
The HELIKIT test is an in vivo diagnostic test for Helicobacter pylori infection; it cannot in any case prejudge the pathology associated with Helicobacter pylori infection.
Adverse Effects
No known adverse reactions.
Reporting suspected adverse reactions
Reporting suspected adverse reactions after authorization of the drug is important.
It allows for ongoing monitoring of the benefit/risk of the drug.
Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Drugs and Health Products (ANSM) and the Network of Regional Pharmacovigilance Centres.